- Home
- BMRA vs SNSE Comparison
BMRA vs SNSE Comparison
Compare BMRA & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- SNSE
- Stock Information
- Founded
- BMRA 1971
- SNSE 2005
- Country
- BMRA United States
- SNSE United States
- Employees
- BMRA N/A
- SNSE N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- SNSE Health Care
- Exchange
- BMRA Nasdaq
- SNSE Nasdaq
- Market Cap
- BMRA 8.1M
- SNSE 9.3M
- IPO Year
- BMRA N/A
- SNSE 2021
- Fundamental
- Price
- BMRA $3.09
- SNSE $8.69
- Analyst Decision
- BMRA
- SNSE Strong Buy
- Analyst Count
- BMRA 0
- SNSE 3
- Target Price
- BMRA N/A
- SNSE $86.67
- AVG Volume (30 Days)
- BMRA 26.1K
- SNSE 12.2K
- Earning Date
- BMRA 04-14-2025
- SNSE 08-05-2025
- Dividend Yield
- BMRA N/A
- SNSE N/A
- EPS Growth
- BMRA N/A
- SNSE N/A
- EPS
- BMRA N/A
- SNSE N/A
- Revenue
- BMRA $5,678,000.00
- SNSE N/A
- Revenue This Year
- BMRA N/A
- SNSE N/A
- Revenue Next Year
- BMRA N/A
- SNSE N/A
- P/E Ratio
- BMRA N/A
- SNSE N/A
- Revenue Growth
- BMRA 5.01
- SNSE N/A
- 52 Week Low
- BMRA $1.93
- SNSE $5.00
- 52 Week High
- BMRA $10.16
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- BMRA 45.39
- SNSE 63.87
- Support Level
- BMRA $3.03
- SNSE $5.86
- Resistance Level
- BMRA $3.44
- SNSE $8.74
- Average True Range (ATR)
- BMRA 0.19
- SNSE 0.75
- MACD
- BMRA 0.01
- SNSE 0.25
- Stochastic Oscillator
- BMRA 43.24
- SNSE 88.54
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).